نتایج جستجو برای: bedaquiline

تعداد نتایج: 462  

2015
Grania Brigden Cathy Hewison Francis Varaine

The current treatment for drug-resistant tuberculosis (TB) is long, complex, and associated with severe and life-threatening side effects and poor outcomes. For the first time in nearly 50 years, there have been two new drugs registered for use in multidrug-resistant TB (MDR-TB). Bedaquiline, a diarylquinoline, and delamanid, a nitromidoxazole, have received conditional stringent regulatory app...

Journal: :Expert opinion on drug safety 2016
H Simon Schaaf Stephanie Thee Louvina van der Laan Anneke C Hesseling Anthony J Garcia-Prats

INTRODUCTION Increasing numbers of children with drug-resistant tuberculosis are accessing second-line antituberculosis drugs; these are more toxic than first-line drugs. Little is known about the safety of new antituberculosis drugs in children. Knowledge of adverse effects, and how to assess and manage these, is important to ensure good adherence and treatment outcomes. AREAS COVERED A Pubm...

2018
Nazir A. Ismail Shaheed V. Omar Lavania Joseph Netricia Govender Linsay Blows Farzana Ismail Hendrik Koornhof Andries W. Dreyer Koné Kaniga Norbert Ndjeka

BACKGROUND Bedaquiline (BDQ) is a novel agent approved for use in combination treatment of multi-drug resistant tuberculosis (MDR-TB). We sought to determine BDQ epidemiological cut-off values (ECVs), define and assess interpretive criteria against putative resistance associated variants (RAVs), microbiological outcomes and cross resistance with clofazimine (CFZ). METHODS A retrospective coho...

Journal: :Cold Spring Harbor perspectives in medicine 2015
Giovanni Sotgiu Rosella Centis Lia D'ambrosio Giovanni Battista Migliori

Tuberculosis is an airborne infectious disease treated with combination therapeutic regimens. Adherence to long-term antituberculosis therapy is crucial for maintaining adequate blood drug level. The emergence and spread of drug-resistant Mycobacterium tuberculosis strains are mainly favored by the inadequate medical management of the patients. The therapeutic approach for drug-resistant tuberc...

2016
Aurélie Chauffour Jérôme Robert Nicolas Veziris Alexandra Aubry Vincent Jarlier

BACKGROUND The treatment of Buruli ulcer (BU) that is caused by Mycobacterium ulcerans, is currently based on a daily administration of rifampin and streptomycin (RIF-STR). A fully oral intermittent regimen would greatly simplify its treatment on the field. METHODOLOGY/PRINCIPAL FINDINGS The objective of this study was to assess the bactericidal and sterilizing activities of intermittent oral...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید